North East and North Cumbria
ICS Formulary
 
back
8 Malignant disease and immunosuppression
08-02 Drugs affecting the immune response

Shared care guidelines are available for:


Blinatumomab Blincyto®
Formulary
  • Approved for use in previously treated Philadelphia-chromosome-negative acute lymphosblastic leukaemia in line with NICE and NHS England Commissioning Policy.
  • Approved for the treatment of acute lymphoblastic leukaemia in remission with minimal residual disease activity in line with NICE
  • Approved as an option to treat Philadelphia-chromosome-negative CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in adults in line with NICE
  • Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm

 
Link  NICE TA1049: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia
Link  NICE TA450 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Link  NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity

Red View adult BNF  View SPC online  View childrens BNF  HCD
Tepotinib Tepmetko®
Formulary
  • Approved for treating advanced non-small-cell lung cancer (NSCLC) with METex14 skipping alterations in adults in line with NICE.
Link  NICE TA789: Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations

Cytotoxic Drug  Red View adult BNF  View SPC online  View childrens BNF  HCD